Eton Pharmaceuticals, Inc. (ETON)
55.36
+3.38
(+6.50%)
USD |
NASDAQ |
Oct 02, 16:00
55.37
+0.01
(+0.02%)
After-Hours: 20:00
Eton Pharmaceuticals Enterprise Value : 1.569B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.569B |
| October 01, 2026 | 1.473B |
| September 30, 2026 | 1.459B |
| September 29, 2026 | 1.677B |
| September 28, 2026 | 1.677B |
| September 25, 2026 | 1.634B |
| September 24, 2026 | 1.685B |
| September 23, 2026 | 1.576B |
| September 22, 2026 | 1.617B |
| September 21, 2026 | 1.567B |
| September 18, 2026 | 1.572B |
| September 17, 2026 | 1.617B |
| September 16, 2026 | 1.597B |
| September 15, 2026 | 1.556B |
| September 14, 2026 | 1.632B |
| September 11, 2026 | 1.617B |
| September 10, 2026 | 1.640B |
| September 09, 2026 | 1.667B |
| September 08, 2026 | 1.681B |
| September 04, 2026 | 1.656B |
| September 03, 2026 | 1.697B |
| September 02, 2026 | 1.755B |
| September 01, 2026 | 1.712B |
| August 31, 2026 | 1.712B |
| August 28, 2026 | 1.694B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.775B |
| August 26, 2026 | 1.774B |
| August 25, 2026 | 1.786B |
| August 24, 2026 | 1.825B |
| August 21, 2026 | 1.798B |
| August 20, 2026 | 1.697B |
| August 19, 2026 | 1.742B |
| August 18, 2026 | 1.797B |
| August 17, 2026 | 1.749B |
| August 14, 2026 | 1.668B |
| August 13, 2026 | 1.157B |
| August 12, 2026 | 1.179B |
| August 11, 2026 | 1.192B |
| August 10, 2026 | 1.238B |
| August 07, 2026 | 1.264B |
| August 06, 2026 | 1.309B |
| August 05, 2026 | 1.303B |
| August 04, 2026 | 1.299B |
| August 03, 2026 | 1.279B |
| July 31, 2026 | 1.316B |
| July 30, 2026 | 1.389B |
| July 29, 2026 | 1.364B |
| July 28, 2026 | 1.322B |
| July 27, 2026 | 1.199B |
| July 24, 2026 | 1.207B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 210.23B |
| Elite Pharmaceuticals, Inc. | 212.92M |
| Daré Bioscience, Inc. | 6.932M |
| Liquidia Corp. | 2.451B |
| ANI Pharmaceuticals, Inc. | 1.893B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.58M |
| Revenue (Quarterly) | 37.59M |
| Total Expenses (Quarterly) | 26.01M |
| EPS Diluted (Quarterly) | 0.3531 |
| Gross Profit Margin (Quarterly) | 67.61% |
| Profit Margin (Quarterly) | 30.80% |
| Earnings Yield | 0.68% |
| Operating Earnings Yield | 0.97% |
| Normalized Earnings Yield | 0.6924 |